The α7nAChR agonists have been shown to improve ischemia-reperfusion kidney injury, cisplatin-related, and LPS-related AKI [22,31,32], but have not been shown to improve AKI in the CLP model, which displays symptoms consistent with SAKI [33]. This evidence concerns the gene CHRNA7 and acute kidney injury.